The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.

doi:10.1128/AAC.40.7.1711

Back to search

Article

The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.

Antimicrobial agents and chemotherapy - 1 Jul 1996

Kew Y, Salomon H, Olsen L R, Wainberg M A, Prasad V R

Abstract excerpt

The alteration of a glutamic acid (E) to a glycine (G) amino acid residue at position 89 (E89G alteration) in the human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to several nucleoside analog inhibitors. Because the nonnucleoside inhibitor-binding pocket...

Topics

Anti-HIV Agents
Drug Resistance, Microbial
Enzyme Inhibitors
HIV Reverse Transcriptase
HIV-1
Mutation
Nucleosides

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.